secwatch / observer
8-K filed May 7, 2026, 7:59 PM ET ticker GILD CIK 0000882095
earnings confidence high sentiment neutral materiality 0.80

Gilead Q1 rev $7.0B (+4% YoY); raises FY rev guidance but slashes EPS guidance due to $11.5B charges

GILEAD SCIENCES, INC.

2026-Q1 EPS reported $1.61 revenue$6,960,000,000
item 2.02item 9.01

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0000882095-26-000022
form_type
8-K
ticker
GILD
cik
0000882095
company_name
GILEAD SCIENCES, INC.
filed_at
2026-05-07T23:59:59+00:00
discovered_at
2026-05-14T18:02:33.859085+00:00
generated_at
2026-05-14T22:21:50.603519+00:00
sec_items
["2.02", "9.01"]
event_type
earnings
sentiment
neutral
materiality_score
0.8
calibrated_materiality_score
0.8
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0000882095-26-000022
json_url
https://secwatch.observer/filing/0000882095-26-000022.json
markdown_url
https://secwatch.observer/filing/0000882095-26-000022.md
text_url
https://secwatch.observer/filing/0000882095-26-000022.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/882095/000088209526000022/0000882095-26-000022-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/882095/000088209526000022/gild-20260507.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null
JSON Markdown Plain text

Source-grounded claims

c975486349857142edf24b0ee7ec008b5a17f87a

GILEAD SCIENCES, INC. reported first quarter 2026 results: revenue $7.0 billion, EPS $1.61. Guidance raised.

in 2026, Gilead is well-positioned for sustained growth in the near and long term.” First Quarter 2026 Financial Results • Total first quarter 2026 revenues increased 4% to $7.0 billion compared to the same period in 2025, primarily driven by higher sales of HIV products, Trodelvy® (sacituzumab govitecan-hziy), and Livdelzi® (seladelpar), partially offset by

SEC 8-K Item 2.02 confidence 0.99 SEC evidence

Comparable filings

VSCO

Victoria's Secret Q1 sales up 15% to $1.56B, beats guidance; raises FY2026 outlook

Victoria's Secret & Co. June 2, 2026, 7:01 AM ET earnings Items 2.02, 7.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

in 2026, Gilead is well-positioned for sustained growth in the near and long term.” First Quarter 2026 Financial Results • Total first quarter 2026 revenues increased 4% to $7.0 billion compared to the same period in 2025, primarily driven by higher sales of HIV products, Trodelvy® (sacituzumab govitecan-hziy), and Livdelzi® (seladelpar), partially offset by

Comparable filing

The Company reported net sales of $1.560 billion for the first quarter of 2026, an increase of 15% compared to net sales of $1.353 billion for the first quarter of 2025 and above the previously communicated guidance range of $1.490 billion to $1.525 billion. Total comparable sales for the first quarter of 2026 increased 13%. The Company reported operating income for the first quarter of 2026 of $76 million compared to operating income of $20 million in the first quarter of 2025. Net income was $48 million, or $0.56 per diluted share, for the first quarter of 2026 compared to net loss of $2 million, or $0.02 per diluted share, for the first quarter of 2025.

Filing page SEC filing

SIG

Signet Q1 sales $1.6B, SSS +1.8%; raises FY27 adjusted EPS guidance

SIGNET JEWELERS LTD June 2, 2026, 6:54 AM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

in 2026, Gilead is well-positioned for sustained growth in the near and long term.” First Quarter 2026 Financial Results • Total first quarter 2026 revenues increased 4% to $7.0 billion compared to the same period in 2025, primarily driven by higher sales of HIV products, Trodelvy® (sacituzumab govitecan-hziy), and Livdelzi® (seladelpar), partially offset by

Comparable filing

On June 2, 2026, Signet Jewelers Limited (the "Company") issued a press release announcing results for the first quarter ended May 2, 2026.

Filing page SEC filing

DG

Dollar General Q1 EPS $2.00 beats expectations; raises FY2026 EPS guidance

DOLLAR GENERAL CORP June 2, 2026, 6:54 AM ET earnings Items 2.02, 5.07, 7.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

in 2026, Gilead is well-positioned for sustained growth in the near and long term.” First Quarter 2026 Financial Results • Total first quarter 2026 revenues increased 4% to $7.0 billion compared to the same period in 2025, primarily driven by higher sales of HIV products, Trodelvy® (sacituzumab govitecan-hziy), and Livdelzi® (seladelpar), partially offset by

Comparable filing

(NYSE: DG) today reported financial results for its first quarter (13 weeks) ended May 1, 2026. First Quarter Fiscal Year 2026 Highlights · Net Sales Increased 3.4% to $10.8 Billion · Same-Store Sales Increased 2.0% · Operating Profit Increased 10.8% to $638.5 Million · Diluted Earnings Per Share (“EPS”) Increased 12.4% to $2.00 · Cash Flow From

Filing page SEC filing

HIVE

HIVE FY2026 revenue $297.8M (+158% YoY); GAAP net loss $148.4M

HIVE Digital Technologies Ltd. June 2, 2026, 6:23 AM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

in 2026, Gilead is well-positioned for sustained growth in the near and long term.” First Quarter 2026 Financial Results • Total first quarter 2026 revenues increased 4% to $7.0 billion compared to the same period in 2025, primarily driven by higher sales of HIV products, Trodelvy® (sacituzumab govitecan-hziy), and Livdelzi® (seladelpar), partially offset by

Comparable filing

EXHIBIT 99.1 HIVE Digital Technologies Ltd.: Exhibit 99.1 - Filed by newsfilecorp.com Exhibit 99.1 HIVE DIGITAL TECHNOLOGIES LTD. HIVE Achieves FY2026 Total Revenue of $297.8 Million (+158% YoY), HIVE's BUZZ HPC Positioned for Growth This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated

Filing page SEC filing

DCI

Donaldson Q3 FY2026 sales $995.1M (+5.8%), adj. EPS $1.06 (+7.1%)

DONALDSON Co INC June 1, 2026, 5:41 PM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

in 2026, Gilead is well-positioned for sustained growth in the near and long term.” First Quarter 2026 Financial Results • Total first quarter 2026 revenues increased 4% to $7.0 billion compared to the same period in 2025, primarily driven by higher sales of HIV products, Trodelvy® (sacituzumab govitecan-hziy), and Livdelzi® (seladelpar), partially offset by

Comparable filing

press release is furnished herewith as Exhibit 99.1. --- EX-99.1 (EX-99.1) --- Donaldson Reports Record Third Quarter Fiscal 2026 Sales and Earnings Third quarter sales of $995.1 million, up 5.8% Operating margin of 15.6%; All-time high adjusted operating margin of 16.6% GAAP EPS of $1.00; Adjusted EPS of $1.06, up 7.1% Closed margin-accretive Facet acquisition,

Filing page SEC filing

GMRS

GMR Solutions Q1 revenue $1.46B (+6.6% YoY), net income $106M (+180% YoY), guides FY26 rev $5.9-6.2B

GMR Solutions Inc. June 1, 2026, 4:45 PM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

in 2026, Gilead is well-positioned for sustained growth in the near and long term.” First Quarter 2026 Financial Results • Total first quarter 2026 revenues increased 4% to $7.0 billion compared to the same period in 2025, primarily driven by higher sales of HIV products, Trodelvy® (sacituzumab govitecan-hziy), and Livdelzi® (seladelpar), partially offset by

Comparable filing

today announced financial results for the first quarter ended March 31, 2026, and full year 2026 financial guidance. First Quarter 2026 Financial Highlights ● Net revenue of $1,457.6 million, up 6.6% compared to $1,367.4 million in the first quarter of 2025 ● Net income of $106.3 million, up 179.7% compared to $38.0 million in the first quarter of 2025 ● Adjusted

Filing page SEC filing

HPE

HPE Q2 FY26: record revenue $10.7B (+40%), raises FY26 guidance, introduces FY27 framework

Hewlett Packard Enterprise Co June 1, 2026, 4:09 PM ET earnings Items 1.01, 2.02, 5.02, 7.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

in 2026, Gilead is well-positioned for sustained growth in the near and long term.” First Quarter 2026 Financial Results • Total first quarter 2026 revenues increased 4% to $7.0 billion compared to the same period in 2025, primarily driven by higher sales of HIV products, Trodelvy® (sacituzumab govitecan-hziy), and Livdelzi® (seladelpar), partially offset by

Comparable filing

gross margin, and non-GAAP diluted net EPS, as well as its highest-ever free cash flow generation for a second quarter. Second Quarter Fiscal 2026 Financial Results • Revenue : $10.7 billion, up 40% from the prior-year period • Gross margins : ◦ GAAP of 36.5%, up 810 basis points from the prior-year period and up 60 basis points sequentially ◦ Non-GAAP (1) of 36.9%,

Filing page SEC filing

CRDO

Credo Q4 revenue $437M (+157% YoY); guides Q1 $465-475M; CEO awarded 1.44M performance-based RSUs

Credo Technology Group Holding Ltd June 1, 2026, 4:08 PM ET earnings Items 2.02, 5.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

in 2026, Gilead is well-positioned for sustained growth in the near and long term.” First Quarter 2026 Financial Results • Total first quarter 2026 revenues increased 4% to $7.0 billion compared to the same period in 2025, primarily driven by higher sales of HIV products, Trodelvy® (sacituzumab govitecan-hziy), and Livdelzi® (seladelpar), partially offset by

Comparable filing

On June 1, 2026, Credo Technology Group Holding Ltd (the "Company") issued a press release announcing its financial results for the fiscal year ended May 2, 2026.

Filing page SEC filing

Source: SEC EDGAR
accession 0000882095-26-000022
view filing index on sec.gov
view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.